


AJICAP[®] Technology: Accelerating the Development of Novel Drug Modalities (Overview)



[Contact us] gdi-info@jp.ajibio-pharma.com

AJICAP[®] technology enables to design versatile antibody-related conjugates.

AJICAP[®] Technology: Novel conjugation and linker technologies




+

Site-specific connection

- ✓ Simple operation
- ✓ No genetic engineering
- ✓ Precise DAR control

Boosting in vivo properties

- ✓ Increasing plasma stability
- ✓ Increasing hydrophilicity
- ✓ Resistant to neutrophil protease




Isotype	mAb
hIgG1	<ul style="list-style-type: none"> ▪ Monoclonal Ab ▪ Chimeric mAb
hIgG2	<ul style="list-style-type: none"> ▪ Engineered mAb ▪ Deglycosylated mAb
hIgG4	<ul style="list-style-type: none"> ▪ BisAb ▪ Fc protein ▪ Polyclonal antibodies
Mouse, Rat antibody	

Conjugation site
Lys248
Lys288
Lys248 & 288

Attachment
Thiol
Azide
DBCO

Payload / Toxins
Small molecule MMAE, Exatecan, PBD etc.
Protein Peptide
Oligonucleotide
Cargo molecule LNP, Liposome etc.
Cell



BIO-PHARMA SERVICES

THE POWER TO MAKE[®]




AJICAP[®] Technology: Accelerating the Development of Novel Drug Modalities (Oligo.)




[Contact us] gdi-info@jp.ajibio-pharma.com


Newly reagent provides high quality DAR1 AOC **without DAR separation process.**



➤ Retained binding to a target receptor.



➤ Higher stability upon incubation.



AJICAP[®] can deliver oligo. conjugates by connecting your mAbs, oligonucleotide.

Step1:


- mAb preparation
- Oligo. design
- Oligo. synthesis



Client

Step3:

- Evaluation (in vitro, in vivo)



BIO•PHARMA SERVICES

THE POWER TO MAKE[®]

